Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Esophagus
Published in: Esophagus 3/2023

Open Access 18-03-2023 | Esophageal Cancer | Special Article

Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1

Authors: Yuko Kitagawa, Ryu Ishihara, Hitoshi Ishikawa, Yoshinori Ito, Takashi Oyama, Tsuneo Oyama, Ken Kato, Hiroyuki Kato, Hirofumi Kawakubo, Hiroshi Kawachi, Shiko Kuribayashi, Koji Kono, Takashi Kojima, Hiroya Takeuchi, Takahiro Tsushima, Yasushi Toh, Kenji Nemoto, Eisuke Booka, Tomoki Makino, Satoru Matsuda, Hisahiro Matsubara, Masayuki Mano, Keiko Minashi, Tatsuya Miyazaki, Manabu Muto, Taiki Yamaji, Tomoki Yamatsuji, Masahiro Yoshida

Published in: Esophagus | Issue 3/2023

Login to get access

Excerpt

The primary objective of these guidelines was to provide general clinicians with information that would guide them to make informed choices from the available diagnosis/treatment strategies for esophageal cancer (intended only for malignant esophageal tumors of epithelial origin, and not for any other non-epithelial malignant tumors of the esophagus or metastatic malignant esophageal tumors). Furthermore, these guidelines are also intended as an aid for healthcare professionals other than physicians, and also for patients and their family members, to help them understand the fundamental principles of the diagnosis and treatment of esophageal cancer. These guidelines are intended to allow physicians to share the information contained therein and promote mutual understanding among healthcare professionals, patients, and the patients’ family members. …
Literature
1.
Watanabe M, Tachimori Y, Oyama T, et al. Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus. 2021;18(1):1–24.PubMedCrossRef
2.
Steevens J, Schouten LJ, Goldbohm RA, et al. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010;59(1):39–48.PubMedCrossRef
3.
Sakata K, Hoshiyama Y, Morioka S, et al. Smoking, alcohol drinking and esophageal cancer: findings from the JACC Study. J Epidemiol. 2005;15(Suppl 2):S212–9.PubMedPubMedCentralCrossRef
4.
Ishiguro S, Sasazuki S, Inoue M, et al. Effect of alcohol consumption, cigarette smoking and flushing response on esophageal cancer risk: a population-based cohort study (JPHC study). Cancer Lett. 2009;275(2):240–6.PubMedCrossRef
5.
Secretan B, Straif K, Baan R, et al. A review of human carcinogens–Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10(11):1033–4.PubMedCrossRef
6.
Oze I, Charvat H, Matsuo K, et al. Revisit of an unanswered question by pooled analysis of eight cohort studies in Japan: Does cigarette smoking and alcohol drinking have interaction for the risk of esophageal cancer? Cancer Med. 2019;8(14):6414–25.PubMedPubMedCentralCrossRef
7.
Druesne-Pecollo N, Tehard B, Mallet Y, et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. Lancet Oncol. 2009;10(2):173–80.PubMedCrossRef
8.
Freedman ND, Park Y, Subar AF, et al. Fruit and vegetable intake and esophageal cancer in a large prospective cohort study. Int J Cancer. 2007;121(12):2753–60.PubMedCrossRef
9.
Yamaji T, Inoue M, Sasazuki S, et al. Fruit and vegetable consumption and squamous cell carcinoma of the esophagus in Japan: the JPHC study. Int J Cancer. 2008;123(8):1935–40.PubMedCrossRef
10.
Lagiou P, Talamini R, Samoli E, et al. Diet and upper-aerodigestive tract cancer in Europe: the ARCAGE study. Int J Cancer. 2009;124(11):2671–6.PubMedCrossRef
11.
Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(3):237–49.PubMedCrossRef
12.
Abnet CC, Freedman ND, Hollenbeck AR, et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer. 2008;44(3):465–71.PubMedPubMedCentralCrossRef
13.
Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31.PubMedCrossRef
14.
Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(5):872–8.PubMedCrossRef
15.
Zhou G, Yuan F, Cai J, et al. Efficacy of prednisone for prevention of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Thorac Cancer. 2017;8(5):489–94.PubMedPubMedCentralCrossRef
16.
Kataoka M, Anzai S, Shirasaki T, et al. Efficacy of short period, low dose oral prednisolone for the prevention of stricture after circumferential endoscopic submucosal dissection (ESD) for esophageal cancer. Endosc Int Open. 2015;3(2):E113–7.PubMed
17.
Pih GY, Kim DH, Gong EJ, et al. Preventing esophageal strictures with steroids after endoscopic submucosal dissection in superficial esophageal neoplasm. J Dig Dis. 2019;20(11):609–16.PubMedCrossRef
18.
Yamaguchi N, Nakao K, Eguchi S, et al. Problems and prospects of treatment for prevention of stenosis after endoscopic submucosal dissection of superficial esophageal cancer-factors associated with resistance to stenosis prevention treatment, and usefulness of steroid oral + local injection combination therapy. Gastroenterol Endosc. 2017;59(10):2535–45.
19.
Kadota T, Yano T, Kato T, et al. Prophylactic steroid administration for strictures after endoscopic resection of large superficial esophageal squamous cell carcinoma. Endosc Int Open. 2016;4(12):E1267–74.PubMedPubMedCentralCrossRef
20.
Hanaoka N, Ishihara R, Uedo N, et al. Refractory strictures despite steroid injection after esophageal endoscopic resection. Endosc Int Open. 2016;4(3):E354–9.PubMedPubMedCentralCrossRef
21.
Hashimoto S, Kobayashi M, Takeuchi M, et al. The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection. Gastrointest Endosc. 2011;74(6):1389–93.PubMedCrossRef
22.
Sato H, Inoue H, Kobayashi Y, et al. Control of severe strictures after circumferential endoscopic submucosal dissection for esophageal carcinoma: oral steroid therapy with balloon dilation or balloon dilation alone. Gastrointest Endosc. 2013;78(2):250–7.PubMedCrossRef
23.
Takahashi H, Arimura Y, Okahara S, et al. A randomized controlled trial of endoscopic steroid injection for prophylaxis of esophageal stenoses after extensive endoscopic submucosal dissection. BMC Gastroenterol. 2015;15:1.PubMedPubMedCentralCrossRef
24.
Ezoe Y, Muto M, Horimatsu T, et al. Efficacy of preventive endoscopic balloon dilation for esophageal stricture after endoscopic resection. J Clin Gastroenterol. 2011;45(3):222–7.PubMedCrossRef
25.
Shibagaki K, Ishimura N, Oshima N, et al. Esophageal triamcinolone acetonide-filling method: a novel procedure to prevent stenosis after extensive esophageal endoscopic submucosal dissection (with videos). Gastrointest Endosc. 2018;87(2):380–9.PubMedCrossRef
26.
Shibagaki K, Yuki T, Taniguchi H, et al. Prospective multicenter study of the esophageal triamcinolone acetonide-filling method in patients with subcircumferential esophageal endoscopic submucosal dissection. Dig Endosc. 2020;32(3):355–63.PubMedCrossRef
27.
Chai NL, Feng J, Li LS, et al. Effect of polyglycolic acid sheet plus esophageal stent placement in preventing esophageal stricture after endoscopic submucosal dissection in patients with early-stage esophageal cancer: a randomized, controlled trial. World J Gastroenterol. 2018;24(9):1046–55.PubMedPubMedCentralCrossRef
28.
Iizuka T, Kikuchi D, Hoteya S, et al. Polyglycolic acid sheet and fibrin glue for preventing esophageal stricture after endoscopic submucosal dissection: a historical control study. Dis Esophagus. 2017;30(11):1–8.PubMedCrossRef
29.
Sakaguchi Y, Tsuji Y, Shinozaki T, et al. Steroid injection and polyglycolic acid shielding to prevent stricture after esophageal endoscopic submucosal dissection: a retrospective comparative analysis (with video). Gastrointest Endosc. 2020;92(6):1176-86.e1.PubMedCrossRef
30.
Ye LP, Zheng HH, Mao XL, et al. Complete circular endoscopic resection using submucosal tunnel technique combined with esophageal stent placement for circumferential superficial esophageal lesions. Surg Endosc. 2016;30(3):1078–85.PubMedCrossRef
31.
Holt BA, Jayasekeran V, Williams SJ, et al. Early metal stent insertion fails to prevent stricturing after single-stage complete Barrett’s excision for high-grade dysplasia and early cancer. Gastrointest Endosc. 2015;81(4):857–64.PubMedCrossRef
32.
Wen J, Lu Z, Yang Y, et al. Preventing stricture formation by covered esophageal stent placement after endoscopic submucosal dissection for early esophageal cancer. Dig Dis Sci. 2014;59(3):658–63.PubMedCrossRef
33.
Ma MW, Gao XS, Gu XB, et al. The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma. World J Surg Oncol. 2018;16(1):172.PubMedPubMedCentralCrossRef
34.
Moreno AC, Zhang N, Verma V, et al. Treatment disparities affect outcomes for patients with stage I esophageal cancer: a national cancer data base analysis. J Gastrointest Oncol. 2019;10(1):74–84.PubMedPubMedCentralCrossRef
35.
Zhao H, Koyanagi K, Kato K, et al. Comparison of long-term outcomes between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma. J Thorac Dis. 2019;11(11):4654–62.PubMedPubMedCentralCrossRef
36.
Morgan MA, Lewis WG, Casbard A, et al. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. Br J Surg. 2009;96(11):1300–7.PubMedCrossRef
37.
Kato K, Ito Y, Nozaki I, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology. 2021;161(6):1878-86.e2.PubMedCrossRef
38.
Ariga H, Nemoto K, Miyazaki S, et al. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;75(2):348–56.PubMedCrossRef
39.
Yamamoto S, Ishihara R, Motoori M, et al. Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma. Am J Gastroenterol. 2011;106(6):1048–54.PubMedCrossRef
40.
Motoori M, Yano M, Ishihara R, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol. 2012;19(7):2135–41.PubMedCrossRef
41.
Park I, Kim YH, Yoon DH, et al. Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience. Cancer Chemother Pharmacol. 2014;74(5):995–1003.PubMedCrossRef
42.
Matsuda S, Tsubosa Y, Niihara M, et al. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy. Ann Surg Oncol. 2015;22(6):1866–73.PubMedCrossRef
43.
Yamauchi K, Iwamuro M, Nakagawa M, et al. Long-term outcomes of endoscopic versus surgical resection for MM-SM1 esophageal squamous cell carcinoma using propensity score analysis. Esophagus. 2021;18(1):72–80.PubMedCrossRef
44.
Suzuki G, Yamazaki H, Aibe N, et al. Endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer: choice of new approach. Radiat Oncol. 2018;13(1):246.PubMedPubMedCentralCrossRef
45.
Nakajo K, Abe S, Oda I, et al. Impact of the Charlson Comorbidity Index on the treatment strategy and survival in elderly patients after non-curative endoscopic submucosal dissection for esophageal squamous cell carcinoma: a multicenter retrospective study. J Gastroenterol. 2019;54(10):871–80.PubMedCrossRef
46.
Koterazawa Y, Nakamura T, Oshikiri T, et al. A comparison of the clinical outcomes of esophagectomy and chemoradiotherapy after noncurative endoscopic submucosal dissection for esophageal squamous cell carcinoma. Surg Today. 2018;48(8):783–9.PubMedPubMedCentralCrossRef
47.
Kawaguchi G, Sasamoto R, Abe E, et al. The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer. Radiat Oncol. 2015;10:31.PubMedPubMedCentralCrossRef
48.
Hisano O, Nonoshita T, Hirata H, et al. Additional radiotherapy following endoscopic submucosal dissection for T1a-MM/T1b-SM esophageal squamous cell carcinoma improves locoregional control. Radiat Oncol. 2018;13(1):14.PubMedPubMedCentralCrossRef
49.
Ikeda A, Hoshi N, Yoshizaki T, et al. Endoscopic Submucosal Dissection (ESD) with additional therapy for superficial esophageal cancer with submucosal invasion. Intern Med. 2015;54(22):2803–13.PubMedCrossRef
50.
51.
Ikawa T, Ishihara R, Konishi K, et al. Failure patterns after adjuvant chemoradiotherapy following endoscopic resection for superficial esophageal squamous cell carcinoma. Cancer Med. 2019;8(10):4547–54.PubMedPubMedCentralCrossRef
52.
Fujita H, Sueyoshi S, Yamana H, et al. Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. World J Surg. 2001;25(4):424–31.PubMedCrossRef
53.
Lee HJ, Lee H, Park JC, et al. Treatment strategy after endoscopic resection of superficial esophageal squamous cell carcinoma: a single institution experience. Gut Liver. 2015;9(6):714–9.PubMedCrossRef
54.
Yoshii T, Ohkawa S, Tamai S, et al. Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer. Dis Esophagus. 2013;26(5):496–502.PubMedCrossRef
55.
Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage I esophageal squamous cell carcinoma. Gastroenterology. 2019;157(2):382–90 (e3).PubMedCrossRef
56.
Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.PubMedCrossRef
57.
Chiu PW, Chan AC, Leung SF, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg. 2005;9(6):794–802.PubMedCrossRef
58.
Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.PubMedCrossRef
59.
Nomura M, Kato K, Ando N, et al. Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A). Jpn J Clin Oncol. 2017;47(6):480–6.PubMedCrossRef
60.
Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2–3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57(2):425–33.PubMedCrossRef
61.
Li XY, Luo HS, Wu SX, et al. Definitive chemoradiation therapy or surgery for clinical T1-3N0-1M0 thoracic esophageal squamous cell carcinoma: a propensity score matching analysis. Asian J Surg. 2019;42(1):350–5.PubMedCrossRef
62.
Chen CY, Li CC, Chien CR. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients. World J Surg Oncol. 2018;16(1):141.PubMedPubMedCentralCrossRef
63.
Wang BY, Wu SC, Chen HC, et al. Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma. Br J Surg. 2019;106(3):255–62.PubMedCrossRef
64.
Naik KB, Liu Y, Goodman M, et al. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: an analysis of the National Cancer Data Base. Cancer. 2017;123(18):3476–85.PubMedCrossRef
65.
Yamashita H, Nakagawa K, Yamada K, et al. A single institutional non-randomized retrospective comparison between definitive chemoradiotherapy and radical surgery in 82 Japanese patients with resectable esophageal squamous cell carcinoma. Dis Esophagus. 2008;21(5):430–6.PubMedCrossRef
66.
Chan R, Morrill S, Freeman D Jr, et al. Bi-modality (chemo-radiation) versus tri-modality (chemo-radiation followed by surgery) treatment for carcinoma of the esophagus. Dis Esophagus. 2001;14(3–4):202–7.PubMedCrossRef
67.
Karran A, Blake P, Chan D, et al. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy. Br J Surg. 2014;101(5):502–10.PubMedCrossRef
68.
Yamashita H, Okuma K, Seto Y, et al. A retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stage II-III esophageal carcinoma. J Surg Oncol. 2009;100(6):435–41.PubMedCrossRef
69.
Yamashita H, Seto Y, Takenaka R, et al. Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: a propensity-matched study. PLoS One. 2017;12(5): e0177133.PubMedPubMedCentralCrossRef
70.
Nomura M, Oze I, Kodaira T, et al. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. Int J Clin Oncol. 2016;21(5):890–8.PubMedCrossRef
71.
Adams R, Morgan M, Mukherjee S, et al. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. Eur J Surg Oncol. 2007;33(3):307–13.PubMedCrossRef
72.
Shao MS, Wong AT, Schwartz D, et al. Definitive or preoperative chemoradiation therapy for esophageal cancer: patterns of care and survival outcomes. Ann Thorac Surg. 2016;101(6):2148–54.PubMedCrossRef
73.
Haefner MF, Lang K, Verma V, et al. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure. Strahlenther Onkol. 2018;194(2):116–24.PubMedCrossRef
74.
Wang BY, Hung WH, Wu SC, et al. Comparison between esophagectomy and definitive chemoradiotherapy in patients with esophageal cancer. Ann Thorac Surg. 2019;107(4):1060–7.PubMedCrossRef
75.
Nagata M, Yamamoto H, Takiguchi N, et al. Neoadjuvant chemoradiotherapy followed by esophagectomy versus definitive chemoradiotherapy in resectable stage II/III (T1–3N0, 1M0) esophageal squamous cell carcinoma. Esophagus. 2006;3(3):105–11.CrossRef
76.
Hsu FM, Lin CC, Lee JM, et al. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study. J Surg Oncol. 2008;98(1):34–41.PubMedCrossRef
77.
Voeten DM, den Bakker CM, Heineman DJ, et al. Definitive chemoradiotherapy versus trimodality therapy for resectable oesophageal carcinoma: meta-analyses and systematic review of literature. World J Surg. 2019;43(5):1271–85.PubMedCrossRef
78.
Li F, Ding N, Zhao Y, et al. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: a systematic review and meta-analysis. Int J Surg. 2018;60:88–100.PubMedCrossRef
79.
Vellayappan BA, Soon YY, Ku GY, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev. 2017;8(8): Cd010511.PubMed
80.
Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81(3):684–90.PubMedCrossRef
81.
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.PubMedCrossRef
82.
Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. 2022;40(4_suppl):238.CrossRef
83.
Takeuchi H, Ito Y, Machida R, et al. A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II/III esophageal squamous cell carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys. 2022;114(3):454–62.PubMedCrossRef
84.
Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47(3):354–60.PubMedCrossRef
85.
86.
Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur J Cancer. 2017;81:183–90.PubMedCrossRef
87.
Xiang M, Chang DT, Heestand GM, et al. Survival after neoadjuvant approaches to gastroesophageal junction cancer. Gastric Cancer. 2020;23(1):175–83.PubMedCrossRef
88.
Spicer JD, Stiles BM, Sudarshan M, et al. Preoperative chemoradiation therapy versus chemotherapy in patients undergoing modified En Bloc esophagectomy for locally advanced esophageal adenocarcinoma: Is radiotherapy beneficial? Ann Thorac Surg. 2016;101(4):1262–9 (discussion 969-70).PubMedCrossRef
89.
Miller JA, Groman A, Yendamuri S, et al. Radiation with neoadjuvant chemotherapy does not improve outcomes in esophageal squamous cell cancer. J Surg Res. 2019;236:259–65.PubMedCrossRef
90.
Klevebro F, Johnsen G, Johnson E, et al. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol. 2015;41(7):920–6.PubMedCrossRef
91.
Zhang Z, Zhang H. Impact of neoadjuvant chemotherapy and chemoradiotherapy on postoperative cardiopulmonary complications in patients with esophageal cancer. Dis Esophagus. 2017;30(4):1–7.PubMedCrossRef
92.
Sunde B, Klevebro F, Johar A, et al. Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial). Br J Surg. 2019;106(11):1452–63.PubMedCrossRef
93.
Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43(7):752–5.PubMedCrossRef
94.
Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol. 2003;21(24):4592–6.PubMedCrossRef
95.
Zhao Y, Dai Z, Min W, et al. Perioperative versus preoperative chemotherapy with surgery in patients with resectable squamous cell carcinoma of esophagus: a phase III randomized trial. J Thorac Oncol. 2015;10(9):1349–56.PubMedCrossRef
96.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.PubMedCrossRef
97.
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.PubMedCrossRef
98.
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203.PubMedCrossRef
99.
Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: Is it a viable therapeutic option? J Clin Oncol. 2015;33(33):3866–73.PubMedCrossRef
100.
Chen Y, Lu Y, Wang Y, et al. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. Dis Esophagus. 2014;27(2):134–40.PubMedCrossRef
101.
Watanabe M, Mine S, Nishida K, et al. Salvage esophagectomy after definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: Who really benefits from this high-risk surgery? Ann Surg Oncol. 2015;22(13):4438–44.PubMedCrossRef
102.
Marks JL, Hofstetter W, Correa AM, et al. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012;94(4):1126–32 (discussion 32-3).PubMedCrossRef
103.
Akutsu Y, Kono T, Uesato M, et al. Is the outcome of a salvage surgery for T4 thoracic esophageal squamous cell carcinoma really poor? World J Surg. 2014;38(11):2891–7.PubMedCrossRef
104.
Kiyozumi Y, Yoshida N, Ishimoto T, et al. Prognostic factors of salvage esophagectomy for residual or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy. World J Surg. 2018;42(9):2887–93.PubMedCrossRef
105.
Slabber CF, Nel JS, Schoeman L, et al. A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus. Am J Clin Oncol. 1998;21(5):462–5.PubMedCrossRef
106.
Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106(4):407–12.PubMedPubMedCentralCrossRef
107.
Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34(10):615–9.PubMedCrossRef
108.
Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501–P2). Int J Radiat Oncol Biol Phys. 2014;89(4):872–9.PubMedCrossRef
109.
Tomblyn MB, Goldman BH, Thomas CR Jr, et al. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol. 2012;7(5):906–12.PubMedPubMedCentralCrossRef
110.
Chiarion-Sileni V, Corti L, Ruol A, et al. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer. 2007;96(3):432–8.PubMedPubMedCentralCrossRef
111.
Yokota T, Kato K, Hamamoto Y, et al. A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 2020;27(2):460–7.PubMedCrossRef
112.
Terada M, Hara H, Daiko H, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Jpn J Clin Oncol. 2019;49(11):1055–60.PubMedCrossRef
113.
Zhao Z, Zhang Y, Wang X, et al. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. Cancer Med. 2020;9(16):5881–8.PubMedPubMedCentralCrossRef
114.
Wu SX, Li XY, Xu HY, et al. Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer. Sci Rep. 2017;7(1):16870.PubMedPubMedCentralCrossRef
115.
Zhang AD, Su XH, Shi GF, et al. Survival comparision of three-dimensional radiotherapy alone vs. chemoradiotherapy for esophageal squamous cell carcinoma. Arch Med Res. 2020;51(5):419–28.PubMedCrossRef
116.
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–7.PubMedCrossRef
117.
Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74.PubMedCrossRef
118.
Hashimoto M, Shirakawa Y, Maeda N, et al. Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer. Esophagus. 2020;17(2):127–34.PubMedCrossRef
119.
Booka E, Haneda R, Ishii K, et al. Appropriate candidates for salvage esophagectomy of initially unresectable locally advanced T4 esophageal squamous cell carcinoma. Ann Surg Oncol. 2020;27(9):3163–70.PubMedCrossRef
120.
Okamura A, Hayami M, Kozuki R, et al. Salvage esophagectomy for initially unresectable locally advanced T4 esophageal squamous cell carcinoma. Esophagus. 2020;17(1):59–66.PubMedCrossRef
121.
Miyata H, Sugimura K, Motoori M, et al. Clinical implications of conversion surgery after induction therapy for T4b thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2019;26(13):4737–43.PubMedCrossRef
122.
Sohda M, Miyazaki T, Sakai M, et al. Multidisciplinary therapy for locally advanced oesophageal cancer with special reference to surgical conversion and salvage. Anticancer Res. 2019;39(6):3167–75.PubMedCrossRef
123.
Ohkura Y, Ueno M, Iizuka T, et al. Prognostic factors and appropriate lymph node dissection in salvage esophagectomy for locally advanced T4 esophageal cancer. Ann Surg Oncol. 2019;26(1):209–16.PubMedCrossRef
124.
Yamaguchi S, Morita M, Yamamoto M, et al. Long-term outcome of definitive chemoradiotherapy and induction chemoradiotherapy followed by surgery for T4 esophageal cancer with tracheobronchial invasion. Ann Surg Oncol. 2018;25(11):3280–7.PubMedCrossRef
125.
Morimoto H, Fujiwara Y, Lee S, et al. Treatment results of neoadjuvant chemoradiotherapy followed by radical esophagectomy in patients with initially inoperable thoracic esophageal cancer. Jpn J Radiol. 2018;36(1):23–9.PubMedCrossRef
126.
Takeuchi M, Kawakubo H, Mayanagi S, et al. The Benefits of docetaxel plus cisplatin and 5-fluorouracil induction therapy in conversion to curative treatment for locally advanced esophageal squamous cell carcinoma. World J Surg. 2019;43(8):2006–15.PubMedCrossRef
127.
Cushman TR, Shaaban SG, Moreno AC, et al. Management of unresectable T4b esophageal cancer: practice patterns and outcomes from the national cancer data base. Am J Clin Oncol. 2019;42(2):154–9.PubMedCrossRef
128.
Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328–34.PubMedPubMedCentralCrossRef
129.
Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22(3):172–6.PubMed
130.
Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001;31(9):419–23.PubMedCrossRef
131.
Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33(8):1216–20.PubMedCrossRef
132.
Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20(10):1667–73.PubMedCrossRef
133.
Moehler M, Maderer A, Thuss-Patience PC, et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol. 2020;31(2):228–35.PubMedCrossRef
134.
Zhang X, Shen L, Li J, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol. 2008;31(1):29–33.PubMedCrossRef
135.
Lee DH, Kim HT, Han JY, et al. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus. Cancer Chemother Pharmacol. 2008;61(1):83–8.PubMedCrossRef
136.
Lee J, Im YH, Cho EY, et al. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol. 2008;62(1):77–84.PubMedCrossRef
137.
Kato K, Muro K, Ando N, et al. A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: the Japan Clinical Oncology Group (JCOG) trial (JCOG 9905-DI). Esophagus. 2014;11(3):183–8.CrossRef
138.
Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16(5):1826–34.PubMedCrossRef
139.
Takahashi H, Arimura Y, Yamashita K, et al. Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol. 2010;5(1):122–8.PubMedCrossRef
140.
Tamura S, Imano M, Takiuchi H, et al. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res. 2012;32(4):1403–8.PubMed
141.
Hironaka S, Tsubosa Y, Mizusawa J, et al. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci. 2014;105(9):1189–95.PubMedPubMedCentralCrossRef
142.
Miyazaki T, Ojima H, Fukuchi M, et al. Phase II study of docetaxel, nedaplatin, and 5-fluorouracil combined chemotherapy for advanced esophageal cancer. Ann Surg Oncol. 2015;22(11):3653–8.PubMedCrossRef
143.
Kataoka K, Tsushima T, Mizusawa J, et al. A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study). Jpn J Clin Oncol. 2015;45(5):494–8.PubMedCrossRef
144.
Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71.PubMedCrossRef
145.
Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–62.PubMedCrossRef
146.
Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–17.PubMedCrossRef
147.
Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–48.PubMedCrossRef
148.
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.PubMedCrossRef
149.
Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65.PubMedCrossRef
150.
Dutton SJ, Ferry DR, Blazeby JM, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014;15(8):894–904.PubMedCrossRef
151.
Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–9.PubMedCrossRef
152.
Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67(6):1265–72.PubMedCrossRef
153.
Yamamoto S, Kawakami H, Kii T, et al. Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201. Eur J Cancer. 2021;154:307–15.PubMedCrossRef
154.
Lordick F, von Schilling C, Bernhard H, et al. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer. 2003;89(4):630–3.PubMedPubMedCentralCrossRef
155.
Jin J, Xu X, Wang F, et al. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol. 2009;4(8):1017–21.PubMedCrossRef
156.
Shim HJ, Cho SH, Hwang JE, et al. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Am J Clin Oncol. 2010;33(6):624–8.PubMedCrossRef
157.
Park BB, Im YH, Hwang IG, et al. Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Invest New Drugs. 2008;26(4):387–92.PubMedCrossRef
158.
Zhang B, Li R, Chang CX, et al. Pemetrexed plus dendritic cells as third-line therapy for metastatic esophageal squamous cell carcinoma. Onco Targets Ther. 2016;9:3901–6.PubMedPubMedCentralCrossRef
159.
Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18(5):631–9.PubMedCrossRef
160.
Kojima T, Yamazaki K, Kato K, et al. Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors. Cancer Sci. 2018;109(10):3253–62.PubMedPubMedCentralCrossRef
161.
Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 2019;5(4):546–50.PubMedCrossRef
162.
Albayrak I, Bagcaci S, Salli A, et al. A rare cause of dysphagia: compression of the esophagus by an anterior cervical osteophyte due to ankylosing spondylitis. Korean J Intern Med. 2013;28(5):614–8.PubMedPubMedCentralCrossRef
163.
Penniment MG, De Ieso PB, Harvey JA, et al. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol. 2018;3(2):114–24.PubMedCrossRef
164.
Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus. 2005;18(3):131–9.PubMedCrossRef
165.
Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 2004;364(9444):1497–504.PubMedCrossRef
166.
Jeene PM, Vermeulen BD, Rozema T, et al. Short-course external beam radiotherapy versus brachytherapy for palliation of dysphagia in esophageal cancer: a matched comparison of two prospective trials. J Thorac Oncol. 2020;15(8):1361–8.PubMedCrossRef
Metadata
Title
Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1
Authors
Yuko Kitagawa
Ryu Ishihara
Hitoshi Ishikawa
Yoshinori Ito
Takashi Oyama
Tsuneo Oyama
Ken Kato
Hiroyuki Kato
Hirofumi Kawakubo
Hiroshi Kawachi
Shiko Kuribayashi
Koji Kono
Takashi Kojima
Hiroya Takeuchi
Takahiro Tsushima
Yasushi Toh
Kenji Nemoto
Eisuke Booka
Tomoki Makino
Satoru Matsuda
Hisahiro Matsubara
Masayuki Mano
Keiko Minashi
Tatsuya Miyazaki
Manabu Muto
Taiki Yamaji
Tomoki Yamatsuji
Masahiro Yoshida
Publication date
18-03-2023
Publisher
Springer Nature Singapore
Published in
Esophagus / Issue 3/2023
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-023-00993-2

Other articles of this Issue 3/2023

Esophagus 3/2023 Go to the issue

Original Article

Risk prediction of esophageal squamous cell carcinoma recurrence in patients who underwent esophagectomy after receiving neoadjuvant treatment: a nationwide retrospective study in Japan

Original Article

Clinical predictors of special type of esophageal cancer

Original Article

Comprehensive analysis of CDK5 as a novel biomarker for progression in esophageal cancer

Original Article

Prognostic impact of desmoplastic reaction in esophageal squamous cell carcinoma patients with neoadjuvant therapy

Original Article

Predictors of the difficulty of transcervical subcarinal lymph node dissection for esophageal cancer

Original Article

Surgical outcomes and quality of life assessment of esophagectomy for cancer with colon conduit via retrosternal route
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits